DE69131699D1 - Verändertes menschliches iL-6 - Google Patents

Verändertes menschliches iL-6

Info

Publication number
DE69131699D1
DE69131699D1 DE69131699T DE69131699T DE69131699D1 DE 69131699 D1 DE69131699 D1 DE 69131699D1 DE 69131699 T DE69131699 T DE 69131699T DE 69131699 T DE69131699 T DE 69131699T DE 69131699 D1 DE69131699 D1 DE 69131699D1
Authority
DE
Germany
Prior art keywords
well
modified human
difficiencies
unglycosylated
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131699T
Other languages
English (en)
Other versions
DE69131699T2 (de
Inventor
Toshifumi Mikayama
Toshihiko Kadoya
Makoto Kakitani
Hideo Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Application granted granted Critical
Publication of DE69131699D1 publication Critical patent/DE69131699D1/de
Publication of DE69131699T2 publication Critical patent/DE69131699T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69131699T 1990-02-13 1991-02-13 Verändertes menschliches iL-6 Expired - Fee Related DE69131699T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3227390 1990-02-13
JP22235390 1990-08-22
JP2250460A JPH04218000A (ja) 1990-02-13 1990-09-21 修飾ポリペプチド

Publications (2)

Publication Number Publication Date
DE69131699D1 true DE69131699D1 (de) 1999-11-18
DE69131699T2 DE69131699T2 (de) 2000-02-24

Family

ID=27287645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131699T Expired - Fee Related DE69131699T2 (de) 1990-02-13 1991-02-13 Verändertes menschliches iL-6

Country Status (9)

Country Link
US (1) US5264209A (de)
EP (1) EP0442724B1 (de)
JP (1) JPH04218000A (de)
AT (1) ATE185602T1 (de)
AU (1) AU634343B2 (de)
CA (1) CA2036197C (de)
DE (1) DE69131699T2 (de)
DK (1) DK0442724T3 (de)
ES (1) ES2136596T3 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006370A1 (en) * 1988-12-01 1990-06-14 The Trustees Of The University Of North Carolina Synthetic interleukin-6
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
MX9304075A (es) * 1992-07-08 1994-04-29 Applied Research Systems Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
AU5098193A (en) * 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
ATE359830T1 (de) * 1993-09-08 2007-05-15 Jolla Pharma Chemisch definierten nicht-polymer wertigen plattformmolokülen und ihren konjugaten
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
CZ288926B6 (cs) * 1994-03-31 2001-09-12 Amgen Inc. MGDF derivát, způsob jeho výroby a farmaceutický prostředek s jeho obsahem
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
EP0785276A4 (de) * 1994-09-29 2002-01-09 Ajinomoto Kk Modifizierung eines peptids und eines proteins
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5861500A (en) * 1996-07-25 1999-01-19 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
US5854398A (en) * 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
CN1168495C (zh) * 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
CN1329082C (zh) 1998-10-16 2007-08-01 拜奥根Idec马萨诸塞公司 干扰素－β－1a的聚合物缀合物及其使用
TR200101087T2 (tr) 1998-10-16 2001-09-21 Biogen, Inc. İnterferon beta-füzyon proteinleri ve kullanımları
KR100719202B1 (ko) 1998-10-23 2007-05-16 키린-암젠 인코포레이티드 ＭＰｌ 수용체에 결합하는 화합물 및 이를 함유하는 제약학적 조성물
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
EP1183230A1 (de) * 1999-06-08 2002-03-06 La Jolla Pharmaceutical Valenz-plattformmoleküle mit aminooxygruppen
US7135461B1 (en) * 2000-06-16 2006-11-14 Myelos Corporation Retro-inverso peptides derived from interleukin-6
EP1270642B1 (de) * 1999-12-24 2011-08-31 Kyowa Hakko Kirin Co., Ltd. Verzweigte polyalkylenglykole
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
JP2003535208A (ja) * 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
SK2772003A3 (en) * 2000-09-08 2003-10-07 Gryphon Therapeutics Inc Synthetic erythropoiesis stimulating proteins
DE10059336A1 (de) * 2000-11-29 2002-06-13 Scil Proteins Gmbh Herstellung von rekombinantem BMP-2
IL142875A (en) * 2001-04-30 2009-08-03 Avigdor Shafferman PEG-linked cholinesterases for the detoxification of circulating organophosphorus
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003243443B2 (en) * 2002-06-21 2008-11-06 Centocor, Inc. Method for generating monoclonal antibodies
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
MXPA05006994A (es) 2002-12-27 2005-10-18 Diobex Inc Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7862816B2 (en) 2003-03-12 2011-01-04 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1491554A1 (de) 2003-06-23 2004-12-29 CONARIS research institute AG PEGlierte lösliche gp130-Dimeren geignet als Medikament
IL159558A0 (en) * 2003-12-24 2004-06-01 Applied Research Systems Use of il-6 in liver injury
WO2005085283A1 (ja) * 2004-03-03 2005-09-15 Yamanouchi Pharmaceutical Co., Ltd. 修飾インターロイキン−１１及びそれを含有する医薬組成物
CN102746401A (zh) 2004-03-12 2012-10-24 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
US20050215710A1 (en) * 2004-03-23 2005-09-29 Gegg Colin V Jr Chemically modified protein compositions and methods
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
AU2005286662B2 (en) * 2004-09-23 2011-10-06 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CN101124243A (zh) 2004-12-23 2008-02-13 莫尔梅德股份有限公司 缀合产物
CN101119743B (zh) 2005-01-31 2012-09-26 株式会社Eci 免疫增强剂
CN101163716B (zh) * 2005-04-30 2011-09-07 成都生物制品研究所 白细胞介素-6聚乙二醇结合物及其制备方法和应用
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
BRPI0618021A2 (pt) * 2005-10-28 2011-08-16 Centocor Inc uso de agentes de expansão de célula b na geração de anticorpos
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
ES2352561T3 (es) 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
AR067536A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
JP5735650B2 (ja) 2010-09-14 2015-06-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｅｇ化エリスロポエチンを精製するための方法
WO2013000872A2 (en) * 2011-06-27 2013-01-03 Galderma Research & Development New th-17 differentiation markers for rosacea and uses thereof
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
US11198721B2 (en) 2014-12-01 2021-12-14 Ferring B.V. Methods for treatment of inflammatory disease or IL-6-mediated condition with gp130 protein
KR20220158870A (ko) 2016-07-15 2022-12-01 에프. 호프만-라 로슈 아게 Ｐｅｇ화 에리트로포이에틴을 정제하기 위한 방법
TW202330584A (zh) * 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) * 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
ES8800982A1 (es) * 1985-07-05 1987-12-01 Takeda Chemical Industries Ltd Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IE67035B1 (en) * 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
EP0585957A1 (de) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Rekombinanter B-Zell-Differenzierungsfaktor
JPS6360938A (ja) * 1986-09-02 1988-03-17 Meiji Milk Prod Co Ltd 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
JPH0372429A (ja) * 1988-10-07 1991-03-27 Chugai Pharmaceut Co Ltd 血小板減少症の治療剤
WO1990006370A1 (en) * 1988-12-01 1990-06-14 The Trustees Of The University Of North Carolina Synthetic interleukin-6

Also Published As

Publication number Publication date
EP0442724A3 (en) 1992-02-26
CA2036197A1 (en) 1991-08-14
CA2036197C (en) 2001-09-18
AU634343B2 (en) 1993-02-18
DE69131699T2 (de) 2000-02-24
ES2136596T3 (es) 1999-12-01
EP0442724B1 (de) 1999-10-13
JPH04218000A (ja) 1992-08-07
EP0442724A2 (de) 1991-08-21
US5264209A (en) 1993-11-23
ATE185602T1 (de) 1999-10-15
AU7087891A (en) 1991-08-15
DK0442724T3 (da) 2000-04-10

Similar Documents

Publication Publication Date Title
DE69131699D1 (de) Verändertes menschliches iL-6
DE69514342T2 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
ATE104348T1 (de) O-glycosyliertes ifn-alpha.
FI916118A (fi) 2-aryl-5-(trifluormetyl)-2-pyrrolin- foereningar och foerfarande foer framstaellning av insekticida 2-aryl-1-(alkoximetyl)-4-halogen-5-(trifluormetyl)pyrroler.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DK35588A (da) Hoejniveau-ekspression i e. coli af oploeseligt, modent humant interleukin-1beta og derivater med aendret biologisk virkning
ATE311399T1 (de) 2'-deoxy-4'-thioribonucleoside als antivirale und antikrebsmittel
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
DK0789583T3 (da) Fremgangsmåder og kits som anvender makrofagstimulerende protein
DE69534738D1 (de) Leukocyten-aktivierender Faktor
ATE123056T1 (de) Ancrod-proteine, ihre herstellung und verwendung.
IT8821173A0 (it) 2 osso 1[[(solfonil)ammino]carbonil]azetidine sostituite in solfonile adattivita' antibatterica.
ATE186731T1 (de) Anomere fluorribosylamine
DE69023331T2 (de) Behandeltes hämoglobin und dessen herstellung.
ATE130872T1 (de) Ancrod ähnliche proteine, ihre herstellung und verwendung.
Harris Breeding biology of the short-billed dowitcher in the Schefferville area, Quebec-Labrador.
ITPN910075A0 (it) Procedimento di costruzione di telai in fibra di carbonio
MX9203129A (es) Proteinas bmp-5.
IT8723080A0 (it) Componente d'arredamento, in particolare del tipo poltrona o simile.
IT1230149B (it) Procedimento per preparare sospensioni di torba ad elevata concentrazione e fluidita'.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee